A5050465341- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Uterine Myomas and Treatments
- Minimally Invasive Surgical Techniques
- Cervical Cancer and HPV Research
- Endometriosis Research and Treatment
- Intraperitoneal and Appendiceal Malignancies
- Sarcoma Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Cancer-related molecular mechanisms research
- Cancer Risks and Factors
- Cardiac, Anesthesia and Surgical Outcomes
- Gynecological conditions and treatments
- Hernia repair and management
- HER2/EGFR in Cancer Research
- Cancer survivorship and care
- Diversity and Career in Medicine
- Cancer Immunotherapy and Biomarkers
- Healthcare Policy and Management
- Surgical Simulation and Training
- Cancer Genomics and Diagnostics
- COVID-19 and healthcare impacts
- Appendicitis Diagnosis and Management
- Estrogen and related hormone effects
- Primary Care and Health Outcomes
Johns Hopkins University
2016-2025
Johns Hopkins Medicine
2016-2025
Johns Hopkins Hospital
2014-2024
Kelly Services (United States)
2016-2024
Indiana University – Purdue University Indianapolis
2023
Michigan Cancer Research Consortium
2023
Indiana University Health
2023
Cleveland Clinic
2007-2023
Cornell University
2023
Woman's Cancer Foundation
2023
The genomes of cancers deficient in mismatch repair contain exceptionally high numbers somatic mutations. In a proof-of-concept study, we previously showed that colorectal with deficiency were sensitive to immune checkpoint blockade antibodies programmed death receptor-1 (PD-1). We have now expanded this study evaluate the efficacy PD-1 patients advanced repair-deficient across 12 different tumor types. Objective radiographic responses observed 53% patients, and complete achieved 21%...
Cervical cancer is a malignant epithelial tumor that forms in the uterine cervix. Most cases of cervical are preventable through human papilloma virus (HPV) vaccination, routine screening, and treatment precancerous lesions. However, due to inadequate screening protocols many regions world, remains fourth-most common women globally. The complete NCCN Guidelines for Cancer provide recommendations diagnosis, evaluation, cancer. This manuscript discusses guiding principles workup, staging,...
Endometrial carcinoma is a malignant epithelial tumor that forms in the inner lining, or endometrium, of uterus. most common gynecologic malignancy. Approximately two-thirds endometrial cases are diagnosed with disease confined to The complete NCCN Guidelines for Uterine Neoplasms provide recommendations diagnosis, evaluation, and treatment cancer uterine sarcoma. This manuscript discusses guiding principles staging, early-stage as well evidence these recommendations.
Purpose Uterine serous carcinoma is a rare, aggressive variant of endometrial cancer. Trastuzumab humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2)/neu, overexpressed in 30% uterine carcinoma. This multicenter, randomized phase II trial compared carboplatin-paclitaxel with and without trastuzumab patients advanced or recurrent who overexpress HER2/neu. Methods Eligible had primary stage III IV HER2/neu-positive disease. Participants were randomly...
Standard first-line chemotherapy for endometrial cancer is paclitaxel plus carboplatin. The benefit of adding pembrolizumab to remains unclear. Download a PDF the Research Summary. In this double-blind, placebo-controlled, randomized, phase 3 trial, we assigned 816 patients with measurable disease (stage III or IVA) stage IVB recurrent in 1:1 ratio receive placebo along combination therapy administration was planned 6 cycles every weeks, followed by up 14 maintenance weeks. were stratified...
The NCCN Guidelines for Cervical Cancer provide interdisciplinary recommendations treating cervical cancer. These Insights summarize the Panel’s discussion and major guideline updates from 2014 2015. recommended systemic therapy options recurrent metastatic cancer were amended upon panel review of new survival data FDA’s approval bevacizumab late-stage This article outlines relevant provides insight into decisions regarding various combination regimens. Additionally, a section was added to...
The NCCN Guidelines for Cervical Cancer provide recommendations diagnostic workup, staging, and treatment of patients with the disease. These Insights focus on recent updates to guidelines, including changes first- second-line systemic therapy recurrent or metastatic disease, emerging evidence a new histopathologic classification system HPV-related endocervical adenocarcinoma.
Abstract Purpose: Uterine-serous-carcinoma (USC) is an aggressive variant of endometrial cancer. On the basis preliminary results a multicenter, randomized phase II trial, trastuzumab (T), humanized-mAb targeting Her2/Neu, in combination with carboplatin/paclitaxel (C/P), recognized as alternative treating advanced/recurrent HER2/Neu-positive USC. We report updated survival analysis NCT01367002. Patients and Methods: Eligible patients had stage III to IV or recurrent disease. Participants...
Endometrial and ovarian cancers can be detected through the analysis of DNA from Pap test fluids, intrauterine samples, plasma.
Adenocarcinoma of the endometrium (also known as endometrial cancer or more broadly uterine carcinoma corpus) is most common malignancy female genital tract in United States. An estimated 49,560 new cases will occur 2013, with 8190 deaths resulting from disease. Uterine sarcomas (stromal/mesenchymal tumors) are uncommon malignancies, accounting for approximately 3% all cancers. The NCCN Guidelines Neoplasms describe malignant epithelial carcinomas and sarcomas; each these major categories...
A study was undertaken to determine recurrence patterns and survival outcomes of stage I uterine papillary serous carcinoma (UPSC) patients.A retrospective, multi-institutional UPSC patients diagnosed from 1993 2006 performed. Patients underwent comprehensive surgical staging; postoperative treatment included observation (OBS); radiotherapy alone (RT); or platinum/taxane-based chemotherapy (CT) +/- RT.The authors identified 142 with a median follow-up 37 months (range, 7-144 months)....
Vulvar cancer is a rare gynecologic malignancy. Ninety percent of vulvar cancers are predominantly squamous cell carcinomas (SCCs), which can arise through human papilloma virus (HPV)–dependent and HPV-independent pathways. The NCCN Cancer panel an interdisciplinary group representatives from Member Institutions consisting specialists in gynecological oncology, medical radiation pathology. Clinical Practice Guidelines Oncology (NCCN Guidelines) for provide evidence- consensus-based approach...
In Brief OBJECTIVE: To describe a technique for contained power morcellation within an insufflated isolation bag at the time of uterine specimen removal during minimally invasive gynecologic procedures. METHODS: Over study period January 2013 to April 2014, 73 patients underwent uterus or myomas hysterectomy myomectomy. This involves placing into large plastic abdomen, exteriorizing opening bag, insufflating peritoneal cavity, and then using morcellator remove in fashion. Procedures were...